Chemical Structure
Cisplatin [15663-27-1]
AG-CR1-3590
CAS Number15663-27-1
Product group Chemicals
Estimated Purity>98%
Molecular Weight300
Overview
- SupplierAdipoGen Life Sciences
- Product NameCisplatin [15663-27-1]
- Delivery Days Customer10
- ADR Class6.1
- CAS Number15663-27-1
- CertificationResearch Use Only
- Estimated Purity>98%
- Hazard InformationDanger,Excepted quantity
- Molecular FormulaCl2H6N2Pt
- Molecular Weight300
- Scientific DescriptionChemical. CAS: 15663-27-1. Formula: Cl2H6N2Pt. MW: 300. Potent platinum-based antineoplastic agent. Anticancer compound. Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death. Nephrotoxic when used in vivo. Potent chemoimmunotherapeutic. Stimulates the immune responses by activating macrophages and other cells of the immune system. Apoptosis inducer via p53-dependent and -independent mechanisms. Induces apoptosis through caspase-3 activation and XIAP expression inhibition. Targets other proteins and enzymes. Non-competitive NHE-1 inhibitor, an archetypal, membrane-bound mechanosensitive sodium-hydrogen ion transporter. - Potent platinum-based antineoplastic agent [1, 10]. Anticancer compound [1]. Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death [2, 12, 13, 15]. Nephrotoxic when used in vivo [3]. Potent chemoimmunotherapeutic. Stimulates the immune responses by activating macrophages and other cells of the immune system [4, 6]. Apoptosis inducer via p53-dependent and -independent mechanisms [5, 7, 8]. Induces apoptosis through caspase-3 activation and XIAP expression inhibition [9, 14]. Targets other proteins and enzymes [10]. Non-competitive NHE-1 inhibitor, an archetypal, membrane-bound mechanosensitive sodium-hydrogen ion transporter [16].
- SMILESN[Pt](N)(Cl)Cl
- Storage Instruction2°C to 8°C
- UN NumberUN 3288
- UNSPSC12352200
References
- Antitumor action of cis-dichlorobis(methylamine)platinum(II): G.R. Gale, et al.; J. Natl. Cancer Inst. 51, 1227 (1973)
- Preliminary characterization of the adducts formed between the antitumor compounds cis-Pt(NH3)2Cl2 and DNA: N.P. Johnson; BBRC 104, 1394 (1982)
- Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity: A.B. Campbell, et al.; Cancer Treat. Rep. 67, 169 (1983)
- Immune response of mice exposed to cis-diamminedichloroplatinum: O. Bagasra, et al.; Cancer Immunol. Immunother. 19, 142 (1985)
- Cisplatin induces a persistent activation of JNK that is related to cell death: I. Sanchez-Perez, et al.; Oncogene 16, 533 (1998)
- Antigen presentation by cisplatin-activated macrophages: role of soluble factor(s) and second messengers: R.A. Singh & A. Sodhi; Immunol. Cell Biol. 76, 513 (1998)
- Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system: M.S. Razzaque, et al.; Histochem. Cell Biol. 111, 359 (1999)
- The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage: J.G. Gong, et al.; Nature 399, 806 (1999)
- Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma: K. Seki, et al.; Cancer Chemother. Pharmacol. 45, 199 (2000)
- What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? J. Lokich; Cancer Invest. 19, 756 (2001)